Team siliconindia

• Amanta Healthcare debuted at a 7% premium over its IPO price.
• Retail investors earned Rs 1,071 per lot, HNIs about Rs 14,994.
• IPO was subscribed 82.61 times, with bids worth Rs 7,286 crore.

Amanta Healthcare entered Dalal Street on a positive note, with its shares listing at a healthy premium over the issue price. The pharmaceutical company’s stock opened at Rs 135 on NSE, which is 7.14% higher than its issue price of Rs 126. On the BSE, it began trading at Rs 134, reflecting a 6.35% premium.

The debut brought quick gains for investors. Retail investors, who were allotted one lot of 119 shares, made a profit of Rs 1,071 on their investment of Rs 14,994. Meanwhile, high-net-worth investors (HNIs) with 14 lots, equal to 1,666 shares worth Rs 2,09,916, earned a profit of Rs 14,994 from the listing.

The performance was in line with market expectations. Before the listing, Amanta Healthcare’s shares were quoting a grey market premium (GMP) of around Rs 9 per share, pointing towards a likely 7–8% listing pop. During the bidding period, the GMP even touched Rs 22–25 per share, showing strong investor appetite.

The company had launched its IPO between September 01 and September 03, with a price band of Rs 120–126 per share and a lot size of 119 shares. Through this issue, Amanta Healthcare raised Rs 126 crore by selling 1 crore fresh equity shares.

Investor response was overwhelming. The IPO was subscribed 82.61 times, receiving more than 13.90 lakh applications and bids worth Rs 7,286 crore. Among the categories, the portion reserved for retail investors was subscribed 54.98 times, while non-institutional investors (NIIs) showed massive interest with 209.42 times subscription. The qualified institutional buyers’ (QIBs) portion was subscribed 35.86 times.

Also Read: Quality & Safety Frameworks to Prevent Medical Errors and Improve Patient Outcomes

Based in Ahmedabad, Amanta Healthcare is a pharmaceutical company known for its sterile liquid and parenteral products. Since its establishment in 1994, the company has specialized in Blow-Fill-Seal and Injection Stretch Blow Moulding technologies. It also manufactures medical devices, further diversifying its portfolio.

Brokerage firms had given a largely positive view on the IPO, advising investors to subscribe for long-term benefits. With the backing of strong fundamentals and advanced manufacturing technology, Amanta Healthcare is seen as well-positioned for future growth.

Beeline Capital Advisors acted as the book running lead manager for the issue, while MUFG Intime India was the registrar.